FDA NDC Directory · JSON-LD · Markdown

Zynteglo

NDC 73554-3111 · CELLULAR THERAPY · SUSPENSION

Generic namebetibeglogene autotemcel
Labeler / ManufacturerGenetix Biotherapeutics Inc.
Marketing categoryBiologic License Application · App BLA125717
Dosage form / routeSUSPENSION · INTRAVENOUS
Active ingredientsBETIBEGLOGENE AUTOTEMCEL (20000000 1/1)
Marketing started20220817
Package count1

External sources

Source: openFDA. Public-domain (CC0).